Drug Profile
REN 213
Latest Information Update: 02 Aug 2004
Price :
$50
*
At a glance
- Originator Renovis
- Class
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postoperative pain
Most Recent Events
- 30 Jul 2004 Discontinued - Phase-II for Postoperative pain in USA (unspecified route)
- 26 Jan 2004 Phase-II clinical trials in Postoperative pain in USA (unspecified route)
- 26 Dec 2003 Phase-I clinical trial completed in Postoperative pain in USA (unspecified route)